Showing results (91-100 of 172) with videos related to

Sort By:
Pageof 18
ESMO Open|December 25, 2021
The impact of COVID-19 on cancer care and oncology clinical research: an experts' perspectiveC Sessa, J Cortes, P Conte, et al.
ESMO Open|December 13, 2021
Management of adverse events from the treatment of encorafenib plus cetuximab for patients with BRAF V600E-mutant metastatic colorectal cancer: insights from the BEACON CRC studyJ Tabernero, L Velez, T L Trevino, et al.
British Journal of Cancer|October 27, 2011
Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trialB Melichar, E Casado, J Bridgewater, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 24, 2016
Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreasR K Ramanathan, D Goldstein, R L Korn, et al.
ESMO Open|December 1, 2022
Pooled safety analysis from phase III studies of trifluridine/tipiracil in patients with metastatic gastric or gastroesophageal junction cancer and metastatic colorectal cancerE Van Cutsem, H Hochster, K Shitara, et al.
Cancer Treatment Reviews|December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug developmentR Stahel, J Bogaerts, F Ciardiello, et al.
ESMO Gastrointestinal Oncology|February 6, 2026
Retreatment with oxaliplatin-based regimens in refractory metastatic colorectal cancer: characterization of high-response patientsF Salvà, G Catani, N Saoudi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 4, 2020
Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensusG Curigliano, S Banerjee, A Cervantes, et al.
Cancer Chemotherapy and Pharmacology|March 5, 2013
A phase I pharmacokinetic study of PM00104 (Zalypsis) administered as a 24-h intravenous infusion every 3 weeks in patients with advanced solid tumorsJ Capdevila, S Clive, E Casado, et al.
Medical Oncology (Northwood, London, England)|November 6, 2010
Feasibility of cetuximab given with a simplified schedule every 2 weeks in advanced colorectal cancer: a multicenter, retrospective analysisM Bouchahda, T Macarulla, G Liedo, et al.
Pageof 18